Caroline Palomeque

Senior Vice President

Caroline Palomeque is a Senior Vice President and Senior Biotechnology Analyst at Maxim Group, LLC. Prior to joining Maxim Group, Ms. Palomeque was a Senior Research Analyst covering the Biotechnology sector at Noble Life Science Partners and WallachBeth Capital. She has equity research experience at Oppenheimer, JMP Securities, Goldman Sachs, and Natexis Bleichroeder. Ms. Palomeque has conducted research at Mount Sinai School of Medicine in molecular epidemiology and neurotoxins. She also co-authored several scientific papers that were published in peer-reviewed academic journals. Ms. Palomeque holds an M.B.A. in Finance from Fordham Graduate School of Business and a B.S. in Neuroscience from the University of Massachusetts Amherst.

Companies Covered


AGRX Agile Therapeutics, Inc.
AZRX AzuRX BioPharma, Inc.
BLPH Bellerophon Therapeutics, Inc.
BCLI Brainstorm Cell Therapeutics
CERC Cerecor Inc.
DARE Dare Bioscience, Inc.
GNPX Genprex, Inc.
IDXG Interpace Diagnostics Group Inc
NTRP Neurotrope, Inc.
OXB.L Oxford BioMedica plc
PMN.TO ProMIS Neurosciences, Inc.
ALQGC.PA Quantum Genomics SA
VTGN VistaGen Therapeutics, Inc.